| Oncogenic mutations of PI3Kalpha result in a constitutively activated enzyme that triggers downstream pathways that increase tumor aggressiveness and survival (Review) | None |
| Structural effects of oncogenic PI3Kalpha mutations. | None |
| Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. | None |
| The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. | None |
| FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide. | None |
| Essential role of Stat3 in PI3K-induced oncogenic transformation. | None |
| Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. | None |
| Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. | None |
| Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein. | None |
| The Proto-oncogene PKCiota regulates the alternative splicing of Bcl-x pre-mRNA. | None |
| Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. | None |
| Our data highlights a new functional synergism between oncogenic EGFR and PIK3CA with WNT/beta-catenin conferring high tolerance to oxidative stress generated by nutrient deprivation. | None |
| Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. | None |
| Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in three-dimensional culture. | None |
| Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). | None |
| Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56. | None |
| Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110alpha/PIK3CA but not by HER2 or mutant AKT1. | None |
| Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth. | None |
| Allosteric activation of PI3Kalpha by oncogenic mutations. | None |
| Oncogenic mutations of p110alpha isoform of PI 3-kinase upregulate its protein kinase activity. | None |